TP53 and myelodysplastic syndrome: In a first case-report study, Jadersten et al. reported the case of a patient with MDS-del(5q) without TP53 mutations at diagnosis, with complete erythroid and partial cytogenetic response to lenalidomide, who evolved to high-risk MDS with a complex karyotype, associated with TP53 mutations [89].